Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambrisentan in Sickle Cell Disease
NCT02712346Phase 1Completed
- Sponsor
- Augusta University
- Start
- Sep 2015
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ambrisentan in sickle cell anemia (SCA) (2 arms), sponsored by Augusta University. Primary endpoint: Safety and Tolerability of ambrisentan. Started Sep 2015; status: completed.
02
Drugs
ambrisentan
03
Conditions
sickle cell anemia (SCA)
Beyond the preview
Go deeper on NCT02712346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02712346.